OOIR: Observatory of International Research

Papers

(The TQCC of Blood Reviews is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Pitfalls in laboratory monitoring of treatment in people with Haemophilia	130
Radiation and leukaemia: Which leukaemias and what doses?	126
Editorial Board	123
Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach	83
Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders	59
Transplant-acquired allergy in HCT-recipients: Reference for clinical management	59
Clinical burden of hemophilia in older adults: Beyond bleeding risk	54
Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond	51
Artificial intelligence in sickle disease	49
Beyond current treatment of Fanconi Anemia: What do advances in cell and gene-based approaches offer?	45
Advances in the critical care management for patients with hematological malignancies	43
The recipe for TACO: A narrative review on the pathophysiology and potential mitigation strategies of transfusion-associated circulatory overload	42
Thalassaemia in China	41
Not all LGL leukemias are created equal	40
Breaking down frailty: Assessing vulnerability in acute myeloid leukemia	39
Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma	39
Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk	38
The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT	38
Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs	38
Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103]	35
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies	35
Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond	34
Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia	34
Chasing leukemia differentiation through induction therapy, relapse and transplantation	33
Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need	33

The acute pain crisis in sickle cell disease: What can be done to improve outcomes?	32
Harnessing multi-source data for individualized care in Hodgkin Lymphoma	32
Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification	31
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions	31
Preservation of fertility in female patients with hematologic diseases	30
Endothelial cells: major players in acute myeloid leukaemia	29
Immune thrombocytopenia: A review of upfront treatment strategies	29
Gut microbiome composition and dysbiosis in immune thrombocytopenia: A review of literature	28
Current challenges in conditioning regimens for MDS transplantation	28
CHIPing away the progression potential of CHIP: A new reality in the making	28
Gut dysbiosis, endotoxemia and clotting activation: A dangerous trio for portal vein thrombosis in cirrhosis	28
Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria	27
A new frontier in Fanconi anemia: From DNA repair to ribosome biogenesis	27
Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines	26
Richter's transformation: Transforming the clinical landscape	26
Optimizing high dose melphalan	25
Down syndrome and leukemia: An insight into the disease biology and current treatment options	25
State-of-the-art review on AL amyloidosis in Western Countries: Epidemiology, health economics, risk assessment and therapeutic management of a rare disease	24
Current state and next-generation CAR-T cells in multiple myeloma	24
Addressing the surge of infections by multidrug-resistant Enterobacterales in hematopoietic cell transplantation	23
ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma	22
The mythological chimera and new era of relapse prediction post-transplant	22
Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia	21
Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?	21
Complementary and alternative medicine for children with sickle cell disease: A systematic review	21
Targeting health-related quality of life in patients with myelodysplastic syndromes – Current knowledge and lessons to be learned	20
Beyond the blood: A practical guide to thalassemia care in the emergency department	20
The role of preoperative transfusion in sickle cell disease, a systematic review and meta-analysis	20
Αlpha-thalassemia: A practical overview	20
Access to CAR T-cell therapy: Focus on diversity, equity and inclusion	19
AML and the art of remission maintenance	19
Improving assessment and management of pain in hemophilia: an Italian Delphi consensus statement	19
Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape	19
The critical role of platelets in venous thromboembolism: Pathogenesis, clinical status, and emerging therapeutic strategies	18
Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?	18
Bridging the evidence-to-practice gap: Advancing neonatal blood transfusion. A narrative review of recent guidelines	18
Navigating acute myeloid leukemia towards better outcomes: Treatment pathways and challenges for patients ineligible for intensive chemotherapy	18
Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy	18
Putting function back in dysfunction: Endothelial diseases and current therapies in hematopoietic stem cell transplantation and cellular therapies	17
Androgen use in bone marrow failures and myeloid neoplasms: Mechanisms of action and a systematic review of clinical data	17
Quality of life, mood disorders, and cognitive impairment in adults with β-thalassemia	16
A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers	16
Innovations in red blood cell preservation	16
Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency	16
Ven the dose matters: Venetoclax dosing in the frontline treatment of AML	16
The future of research in hematology: Integration of conventional studies with real-world data and artificial intelligence	15
Tackling myeloma bone disease: From pathophysiology to cutting-edge therapies	15
The use of bone-modifying agents in multiple myeloma	15
Perspective – The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021	15
How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy?	15

Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment